Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in pediatric and adolescent type 2 diabetes
NCT05260021Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2022
- Primary completion
- Jul 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c at 30 weeks. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05260021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260021.